Skip to main content

Table 2 Symptoms and vital signs at the time of admission

From: Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study

 

No Bacterial Infection (n = 1635)

Respiratory Co-infection (n = 54)

Respiratory Secondary Infection (n = 85)

P value

Fever

37.2 ± 0.92

37.6 ± 1.03

37.4 ± 1.15

0.004 a=**

Cough

1009 (58.8%)

27 (50.0%)

44 (58.7%)

0.43

Sputum

402 (23.5%)

21 (38.9%)

25 (33.8%)

0.005

Sore throat

409 (24.0%)

9 (17.0%)

9 (12.00%)

0.03

Nasal discharge

260 (15.2%)

4 (7.69%)

5 (6.67%)

0.04

Dysgeusia

318 (18.6%)

4 (7.84%)

6 (8.11%)

0.01

Dysosmia

283 (16.6%)

5 (9.80%)

4 (5.41%)

0.02

Dyspnea

513 (30.4%)

28 (51.9%)

35 (48.0%)

 < 0.0001

Disturbance of consciousness

50 (2.91%)

8 (13.0%)

9 (12.2%)

 < 0.0001

Malaise

835 (48.7%)

31 (57.4%)

42 (56.8%)

0.19

Systolic blood pressure

129.2 ± 19.6

129.8 ± 21.9

130.6 ± 27.4

0.83

Diastolic blood pressure

80.6 ± 13.5

79.6 ± 13.7

77.1 ± 13.9

0.09

Heart rate

87.2 ± 16.6

93.7 ± 19.6

86.7 ± 18.8

0.02a=*

Respiratory Rate

19.2 ± 4.58

20.7 ± 5.47

21.8 ± 6.47

 < 0.0001b=**

SpO2

96.0 ± 3.07

93.7 ± 4.95

95.3 ± 3.04

 < 0.0001a=**

  1. Data are expressed as number (percentage) or mean ± SD
  2. *p < 0.05
  3. **p < 0.01
  4.  aComparison of patients without infection versus patients with community-acquired co-infection
  5.  bComparison of patients without infection versus patients with hospital-acquired secondary infection